Literature DB >> 18672224

The epidemiology of progression of pure geographic atrophy: the Beaver Dam Eye Study.

Ronald Klein1, Stacy M Meuer, Michael D Knudtson, Barbara E K Klein.   

Abstract

PURPOSE: To examine the change in size and location of pure geographic atrophy (GA).
DESIGN: Population-based cohort study.
METHODS: Ninety-five persons with GA either at baseline or at the one of the three five-year follow-up examinations, or both, were identified. Using computer-assisted software, the lesion area and greatest linear dimension (GLD) were calculated. Thirty-two persons (53 multiple eye-visit pairs) were seen at multiple visits five years apart with GA in the same eye to evaluate changes in total area and GLD.
RESULTS: At the first occasion when pure GA was identified (n = 95), 45% had a single GA lesion, 18% had multifocal GA lesions, and 37% had a merged GA lesion. Of 53 eyes with multiple visits, the overall increase in atrophy was 6.4 mm(2) over a five-year period. The atrophy progressed to involve the foveal center in 47% of 19 eyes, and there was a mean decrease of 17 letters read correctly. Eyes with multifocal GA were most likely to have the area of atrophy increase (mean, 12 mm(2)), to have atrophy progress to the foveal center (83%), and to have a decrease in vision (mean, 22 letters), whereas eyes with a single GA lesion were least likely to have the area of atrophy increase (mean, 2 mm(2)), to have the lesion progress to the foveal center (22%), and to have a decrease in vision (mean, 10 letters).
CONCLUSIONS: These are the first population-based data describing the five-year change in eyes with pure GA. Information on progression of GA will be useful for clinical trials of new interventions for GA.

Entities:  

Mesh:

Year:  2008        PMID: 18672224      PMCID: PMC2612630          DOI: 10.1016/j.ajo.2008.05.050

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

1.  Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study.

Authors:  Redmer van Leeuwen; M Kamran Ikram; Johannes R Vingerling; Jacqueline C M Witteman; Albert Hofman; Paulus T V M de Jong
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-09       Impact factor: 4.799

2.  Risk factors for age-related macular degeneration: Pooled findings from three continents.

Authors:  W Smith; J Assink; R Klein; P Mitchell; C C Klaver; B E Klein; A Hofman; S Jensen; J J Wang; P T de Jong
Journal:  Ophthalmology       Date:  2001-04       Impact factor: 12.079

3.  Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study.

Authors:  Paul Mitchell; Jie Jin Wang; Suriya Foran; Wayne Smith
Journal:  Ophthalmology       Date:  2002-06       Impact factor: 12.079

4.  Changes in visual acuity in a population over a 10-year period : The Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; K E Lee; K J Cruickshanks; R J Chappell
Journal:  Ophthalmology       Date:  2001-10       Impact factor: 12.079

5.  Causes and prevalence of visual impairment among adults in the United States.

Authors:  Nathan Congdon; Benita O'Colmain; Caroline C W Klaver; Ronald Klein; Beatriz Muñoz; David S Friedman; John Kempen; Hugh R Taylor; Paul Mitchell
Journal:  Arch Ophthalmol       Date:  2004-04

6.  Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: the Blue Mountains Eye Study cohort.

Authors:  Jie Jin Wang; Suriya Foran; Wayne Smith; Paul Mitchell
Journal:  Arch Ophthalmol       Date:  2003-05

7.  The risk and natural course of age-related maculopathy: follow-up at 6 1/2 years in the Rotterdam study.

Authors:  Redmer van Leeuwen; Caroline C W Klaver; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong
Journal:  Arch Ophthalmol       Date:  2003-04

8.  Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Stacy M Meuer; Guan-Hua Huang
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

9.  Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.

Authors:  Peter K Kaiser; David M Brown; Kang Zhang; Henry L Hudson; Frank G Holz; Howard Shapiro; Susan Schneider; Nisha R Acharya
Journal:  Am J Ophthalmol       Date:  2007-10-22       Impact factor: 5.258

10.  The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  Ronald Klein; Barbara E K Klein; Sandra C Tomany; Karen J Cruickshanks
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

View more
  38 in total

1.  Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry.

Authors:  Annal D Meleth; Pradeep Mettu; Elvira Agrón; Emily Y Chew; Srinivas R Sadda; Frederick L Ferris; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-28       Impact factor: 4.799

2.  Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial.

Authors:  Wai T Wong; Waynekid Kam; Denise Cunningham; Molly Harrington; Keri Hammel; Catherine B Meyerle; Catherine Cukras; Emily Y Chew; Srinivas R Sadda; Frederick L Ferris
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

Review 3.  [Clinical characteristics, progression and risk factors of geographic atrophy].

Authors:  C K Brinkmann; C Adrion; U Mansmann; S Schmitz-Valckenberg; F G Holz
Journal:  Ophthalmologe       Date:  2010-11       Impact factor: 1.059

4.  Progression of geographic atrophy in age-related macular degeneration imaged with spectral domain optical coherence tomography.

Authors:  Zohar Yehoshua; Philip J Rosenfeld; Giovanni Gregori; William J Feuer; Manuel Falcão; Brandon J Lujan; Carmen Puliafito
Journal:  Ophthalmology       Date:  2010-10-29       Impact factor: 12.079

5.  Ten-year follow-up of eyes treated with stereotactic fractionated external beam radiation for neovascular age-related macular degeneration.

Authors:  Rupan Trikha; Lawrence S Morse; Robert J Zawadzki; John S Werner; Susanna S Park
Journal:  Retina       Date:  2011 Jul-Aug       Impact factor: 4.256

6.  Selective retina therapy (SRT) in patients with geographic atrophy due to age-related macular degeneration.

Authors:  Philipp Prahs; Andreas Walter; Roman Regler; Dirk Theisen-Kunde; Reginald Birngruber; Ralf Brinkmann; Carsten Framme
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-12-22       Impact factor: 3.117

Review 7.  Fundus autofluorescence imaging in dry AMD: 2014 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Frank G Holz; Julia S Steinberg; Arno Göbel; Monika Fleckenstein; Steffen Schmitz-Valckenberg
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-19       Impact factor: 3.117

8.  Incidence and Growth of Geographic Atrophy during 5 Years of Comparison of Age-Related Macular Degeneration Treatments Trials.

Authors:  Juan E Grunwald; Maxwell Pistilli; Ebenezer Daniel; Gui-Shuang Ying; Wei Pan; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Maureen G Maguire; Daniel F Martin
Journal:  Ophthalmology       Date:  2016-10-27       Impact factor: 12.079

9.  VISUAL FUNCTION MEASURES IN EARLY AND INTERMEDIATE AGE-RELATED MACULAR DEGENERATION.

Authors:  Arthika Chandramohan; Sandra S Stinnett; John T Petrowski; Stefanie G Schuman; Cynthia A Toth; Scott W Cousins; Eleonora M Lad
Journal:  Retina       Date:  2016-05       Impact factor: 4.256

10.  Evaluation of Geographic Atrophy from Color Photographs and Fundus Autofluorescence Images: Age-Related Eye Disease Study 2 Report Number 11.

Authors:  Amitha Domalpally; Ronald Danis; Elvira Agrón; Barbara Blodi; Traci Clemons; Emily Chew
Journal:  Ophthalmology       Date:  2016-07-19       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.